Logo
x

Search

Subscribe Now

Duchenne Muscular Dystrophy

Disease of the Month: Duchenne Muscular Dystrophy (DMD)

Disease of the Month: Duchenne Muscular Dystrophy (DMD)

  • September 29, 2022
Santhera and ReveraGen Report Results of Vamorolone in P-IIb VISION-DMD Study for Duchenne Muscular Dystrophy

Santhera and ReveraGen Report Results of Vamorolone in P-IIb VISION-DMD Study for Duchenne Muscular Dystrophy

  • June 1, 2021
Sarepta's SRP-9001 Demonstrates Robust Expression and Safety Results in ENDEAVOR Study for DMD

Sarepta's SRP-9001 Demonstrates Robust Expression and Safety Results in ENDEAVOR Study for DMD

  • May 19, 2021
FibroGen Initiates P-III LELANTOS-2 Study of Pamrevlumab for Duchenne Muscular Dystrophy

FibroGen Initiates P-III LELANTOS-2 Study of Pamrevlumab for Duchenne Muscular Dystrophy

  • March 17, 2021
Sarepta Reports Mixed Results of SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) in Part 1 of Study 102 for DMD

Sarepta Reports Mixed Results of SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) in Part 1 of Study 102 for DMD

  • January 8, 2021
Santhera Halts P-III SIDEROS Study Evaluating Puldysa in Patients with DMD

Santhera Halts P-III SIDEROS Study Evaluating Puldysa in Patients with DMD

  • October 6, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.